no code implementations • 28 Nov 2023 • Yuqi Wang, Aarzu Gupta, David Carpenter, Trey Mullikin, Zachary J. Reitman, Scott Floyd, John Kirkpatrick, Joseph K. Salama, Paul W. Sperduto, Jian-Guo Liu, Mustafa R. Bashir, Kyle J. Lafata
We evaluated our method on multiple clinically-relevant endpoints, including time to intracranial progression (ICP), progression-free survival (PFS) after SRS, overall survival (OS), and time to ICP and/or death (ICPD), on a variety of both statistical and non-statistical models, including CoxPH, conditional survival forest (CSF), and neural multi-task linear regression (NMTLR).